Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
Certara2024 年 8 月 19 日
Optimizing Clinical Development: Saving Time and Costs
战略机械建模解决方案可帮助免疫肿瘤生物技术加速其新型疗法的临床开发。
Certara2024 年 8 月 16 日
Medicines that matter: Biohaven’s Nurtec™ drug development journey
In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved…
Certara2024 年 8 月 15 日
Model-Informed Confidence in Oncology Dose Selection
Discover an oncology-focused company that gained confidence in their dose selection for an AML trial…
Certara2024 年 8 月 9 日
Certara’s MIDD Oncology Capabilities
Improve Oncology Study Decisions with Certara's MIDD Team Transcript: The pace of oncology drug…
Certara2024 年 8 月 7 日
Systems Modeling Delivers Efficiencies and Savings in Clinical Development
Discover how an IO-focused company developing immunotherapies applied QSP modeling solutions for cost-effective clinical development.…
Certara2024 年 7 月 12 日
Accelerating the Progress of Kinase Inhibitors in Oncology
The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…
Certara2024 年 5 月 20 日
How to Navigate the FDA Landscape for an Orphan Drug
罕见病是公共卫生领域的优先事项。FDA has launched several programs and a final…
Certara2024 年 2 月 21 日
